Last reviewed · How we verify

Licartin and CIK — Competitive Intelligence Brief

Licartin and CIK (Licartin and CIK) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (Licartin); Adoptive cell therapy (CIK). Area: Oncology.

marketed Monoclonal antibody (Licartin); Adoptive cell therapy (CIK) HAb18G/CD147 antigen (Licartin); Multiple (CIK cells) Oncology Biologic Live · refreshed every 30 min

Target snapshot

Licartin and CIK (Licartin and CIK) — Tianjin Medical University Cancer Institute and Hospital. Licartin is a recombinant human-mouse chimeric monoclonal antibody targeting hepatocellular carcinoma cells, while CIK refers to cytokine-induced killer cells used in adoptive cell immunotherapy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Licartin and CIK TARGET Licartin and CIK Tianjin Medical University Cancer Institute and Hospital marketed Monoclonal antibody (Licartin); Adoptive cell therapy (CIK) HAb18G/CD147 antigen (Licartin); Multiple (CIK cells)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (Licartin); Adoptive cell therapy (CIK) class)

  1. Tianjin Medical University Cancer Institute and Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Licartin and CIK — Competitive Intelligence Brief. https://druglandscape.com/ci/licartin-and-cik. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: